Singular Research Initiates Coverage of Nymox With "Buy" Rating
July 21, 2010 11:12 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., July 21, 2010 (GLOBE NEWSWIRE) -- Singular Research has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with a "Buy" rating and a 12 month target price of...
Nymox Reports Positive New Clinical Trial Data on Improvement in Key Symptom in Patients on NX-1207 Drug for Prostate Enlargement
July 07, 2010 11:41 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., July 7, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new results from pooled analysis of completed clinical trials of...
Nymox Announces New U.S. Follow-Up Results From Study NX02-0014, BPH Drug NX-1207 Continues to Show Positive Data at 5 Years
June 22, 2010 11:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 22, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report positive new results from the 48-60 month follow-up study of patients...
Nymox Reports Near Completion of New Five Year Long-Term Follow-Up NX02-0014 U.S. Study of BPH Drug
June 15, 2010 09:50 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 15, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term...
Nymox to Present at Jefferies 2010 Global Life Sciences Conference
June 07, 2010 10:58 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 7, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox,...
New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting
June 02, 2010 09:15 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 2, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation of new positive data at a high-level symposium and...
Nymox NX-1207 Symposium at American Urological Association Annual Meeting in San Francisco Tuesday June 1 at 3:00 p.m. PDT
May 27, 2010 12:17 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 27, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the presenters and participants for the symposium and panel discussion...
Nymox Announces 3 Year Follow-Up Results From NX02-0016 U.S. Study of NX-1207 for BPH
May 25, 2010 09:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 25, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report positive new results from the 30-36 month follow-up study of patients...
Symposium on Nymox's NX-1207 BPH Drug to be Held at Annual Meeting of American Urological Association in San Francisco
May 20, 2010 09:50 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 20, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a symposium and panel discussion devoted to progress in the...
Nymox Nears Completion of New Three Year U.S. Long-Term Follow-Up Study of BPH Drug
May 18, 2010 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 18, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term...